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SUMMARY 
Patients with septic shock by multidrug resistant microorganisms (MDR) are a specific sepsis 
population with a high mortality risk. The exposure to an initial inappropriate empiric antibiotic 
therapy has been considered responsible for the increased mortality, although other factors such 
as immune-paralysis seem to play a pivotal role. Therefore, beyond conventional early antibiotic 
therapy and fluid resuscitation, this population may benefit from the use of alternative strategies 
aimed to support the immune system. In this review we present an overview of the relationship 
between MDR infections and immune-response and focus on the rationale and the clinical data 
available on the possible adjunctive immunotherapies, including blood purification techniques and 
different pharmacological approaches.  
  
 INTRODUCTION 
 Since early 90s, the American College of Chest Physicians and Society of Critical Care 
Medicine Consensus Conference has placed great emphasis to sepsis and its definition [1]. The 
definitions issued by 1991 Consensus Conference are the followings: sepsis was defined as an 
infectious insult with systemic inflammatory response syndrome (SIRS) while severe sepsis has 
been associated with organ dysfunction and septic shock, finally, it has been identified as 
hypotension or hypoperfusion refractory to adequate fluid resuscitation. More recently, the Third 
International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) revised the definitions 
emphasizing especially the role of the host response and the related pathophysiological problems 
[2]. In Sepsis-3 the definition of severe sepsis was eliminated as well as the role of SIRS was 
downgraded by defining sepsis as an organ dysfunction distant from the primary site of infection, 
whereas septic shock was more strictly related to increased mortality. The change of perspective 
from invading pathogens to the host response has radically transformed the vision of sepsis 
pathobiology in the last decades. The current concepts indicate that the sepsis processes develop 
on a double track sustained both by products of infecting microorganisms and by endogenous 
mediators derived from complement activation and by specific cell-surface receptors expressed on 
immune, epithelial and endothelial cells. In this way, a complex system of intracellular signals is 
created by the binding of pathogen-associated molecular patterns (PAMPs) and damage-
associated molecular patterns (DAMPs) [3]. The development of these multiple intracellular 
signals leads to the expression of several common gene classes that are involved in inflammation, 
adaptive immunity and cellular metabolism. More specifically, the recognition of PAMPs and 
DAMPs produces the recruitment of pro-inflammatory intermediates that initiate the expression 
of early activation genes [4]. 
 
SEPSIS RELATED IMMUNE PARALYSIS 
 It became clear that the host response may be hyper or hypo-reactive, or both at different 
time, with an overwhelming inflammation associated to a boost of pro-inflammatory cytokines in 
the former and an immune paralysis with the prevalence of anti-inflammatory cytokines and 
cellular apoptosis in the latter. Although pro-inflammatory and anti-inflammatory responses may 
occur simultaneously, early phases of sepsis are usually characterized by hyper-inflammatory 
processes associated to classical clinical signs ranging from slight to severe impairment of organ 
function, including shock appearance [5]. On the other hand, Immune suppressive state becomes 
predominant in later stages of sepsis producing the so call persistent 
inflammation/immunosuppression and catabolism syndrome (PICS)[6]. Despite the precise 
mechanisms are still unclear, the hypothesis for explaining the development and maintenance of 
PICS are mainly two: i) a persistent and dysregulated activity of PAMPs, DAMPs, inflammasomes 
and tissue “alarmins”  and ii) the role of opportunistic infections (e.g. viral reactivation, infection 
Acinetobacter spp), changes in the host microbiota and invasive procedures performed in critically 
ill patients [4]. Sepsis related immunosuppression causes profound changes in both the innate and 
adaptive immunity [7, 8] with persistent lymphopenia and high level of immature forms of 
myeloid cells. The dysfunction of immune system during sepsis prone patients, particularly those 
with severe comorbidities or multiple surgical interventions, to colonization and infections, 
including breakthrough infections, by opportunistic nosocomial multi-drug resistant (MDR) 
bacteria. Therefore, patients carrying MDR bacteria should be considered a special population 
requiring specific strategies directed to supported immune system beyond the sole antibiotic 
therapy .  
PATIENTS WITH MDR BACTERIA: WHY THEY ARE A SPECIAL POPULATION? 
 Sepsis and septic shock related to MDR bacteria are progressively increasing in the last 
decades with gram negative pathogens responsible for the majority of cases [9]. International 
guidelines define MDR bacteria as microorganisms non-susceptible in vitro to at least three 
different antimicrobial categories (previously excluding intrinsic resistance), XDR as non-
susceptible to at least one agent in all but two or fewer antimicrobial categories and PDR as 
resistant to any agents in all antimicrobial classes tested [10]. The burden of infections sustained 
by MDR bacteria is variable in different areas: world data show a lower incidence in northwest of 
Europe, USA and Canada a higher incidence in southeast of Europe, Latin America and Asia Pacific 
[11]. According to recent studies, from one third to the half of intensive care unit (ICU) acquired 
infections are sustained by MDR bacteria and among gram negative Acinetobacter spp., Klebsiella 
pneumoniae, and Pseudomonas spp. are the most common isolates [12]. The ability of these 
bacteria to survive for prolonged time in the hospital environment, the facility of transfer among 
patients and healthcare staff together with the antibiotic resistance are responsible for their 
increasingly widespread. To note that MDR infections are progressively more common also in 
community acquired infections and the acquisition of these pathogens through travels in different 
world regions is becoming frequent.  
 MDR infections influences patients’ outcome with higher mortality rates in metallo-β-
lactamases Enterobacteriaceae and Pseudomonas aeruginosa and in carbapenem-resistent 
Klebsiella pneumoniae, likely due to the delay in the appropriate antimicrobial therapy [13]. The 
Centre for control of Diseases calculates that gram negative MDR infections are responsible for 
approximately 40,000 cases and more than 2,800 deaths in the United States (CDC 2013 Threat 
report). It is well known that a goal in the management of septic shock is the administration of 
intravenous antimicrobials within the first hour of diagnosis and an initial non-effective therapy is 
related to increase mortality [14]. In MDR infections, the choice of an appropriate antimicrobial 
treatment is truly more complicate. In patients with bloodstream infections sustained by ESBL 
producing bacteria the 3-week mortality in patients with an initial inadequate therapy was 60% 
compared to 19% in those receiving the appropriate one [15]. Ivady et al. observed in a pediatric 
population with gram-negative bloodstream infection that MDR acquisition was associated with 
polymicrobial infections and higher risk of evolution in septic shock and multiple organ failure 
[16].  
The relationship between MDR infections and the host immune response is so far unclear. 
A recent study described the interactions between different clones and resistance phenotypes of 
Klebsiella pneumoniae and innate immune response. In vitro stimulation of human peripheral 
blood mononuclear cells (PBMCs) with different heat-killed isolates of K. pneumoniae led to 
different patterns of TNF-α production. In particular, the highly virulent KPC-producing isolates of 
the ST17 clones are associated with low release of both TNF-α and IL-17 mediated by toll like 
receptor 9 that may contribute to a state of immunosuppression [17]. A similar work on P. 
aeruginosa showed that antibiotic susceptible isolates induce a significantly higher production of 
IL-1β and IL-6 and by human monocytes compared to MDR ones [18]. These results suggest that 
multi-drug resistance could play a role in the modulation of host both innate and adaptive 
immune response. However, further studies are needed to better understand this complex 
relationships and the potential relevance of a specific immunomodulatory therapy in these 
infections.  
THE ROLE OF IMMUNE ADJUVANT THERAPIES IN MDR INFECTIONS 
 As described above, immune paralysis is an important hallmark in patients colonized or 
infected by MDR bacteria. These observations associated with the characteristics of most patients 
affected by sepsis and septic shock (e.g. elderly, oncologic, with liver and/or renal chronic 
dysfunction, treated with immunosuppressive drugs) and with the difficulties related to the 
antibiotic resistance of pathogens make attractive the development of new immune stimulatory 
therapies to improve the prognosis. So far, despite many treatments have been investigated on 
animal models, only few have been used in patients.  
Extracorporeal blood purification techniques 
 Different extracorporeal blood purification techniques have been recently developed and 
tested to remove inflammatory mediators and, thus, modify immune cell functions. Among these 
techniques, two meta-analyses showed no benefits by the use of high volume hemofiltration 
appears in septic patients [19, 20], whereas cascade hemofiltration, using two different filters (the 
first with an elevated cut-off and the second with a low cut-off) able to remove middle molecular 
weight molecules such as cytokines but, after promising results in an animal model [21], seems to 
have no effects on the need for catecholamines as recently demonstrated in 60 patients with 
septic shock [22]. The use of hemoperfusion with polymyxin-B cartridge showed contrasting 
results in different trials [23, 24]. Plasma exchange seems to be effective in the removal of 
cytokines and the association between plasma filtration and adsorption (CPFA) could be even 
more efficient leading to an improvement of immune paralysis with an increase in HLA-DR 
expression on monocytes and a restored lipopolysaccharide (LPS)-induced TNF-α production [25]. 
Unfortunately, a recent randomized control trial in patients with septic shock did not show 
significant benefits by the use of CPFA. Highly adsorptive membranes and high cut-off membranes 
can also be used to obtain a blood purification and the progressive optimization of these 
techniques will lead to preservation of useful molecules and a more selective removal of 
inflammatory mediators [26].  
Pharmacological approaches  
  Another way to interfere in host immune response is the use of different molecules able to 
modulate the immune system. Granulocytes-macrophage colony stimulating factor (GM-CSF) and 
interferon-γ (INF-γ) have been proposed and used because of their effects on antigen presenting 
cells whose function in septic shock is deeply impaired. A meta-analysis on randomized, placebo vs 
GM-CSF trials in septic shock showed a better infection clearance in treated patients but no 
improvement in 28-day mortality. To note that the trial with GM-CSF administration guided by 
mHLA-DR expression observed a reduced use of mechanical ventilation and a shorter ICU and 
hospital length of stay in treated patients [27]. INF- γ has been also administrated in subjects with 
trauma and burns with contradictory results. Again, it is to underline that, in burn patients with 
significant reduction of HLA-DR expression on monocytes, its use concomitant to GM-CSF was able 
to increase HLA-DR and to restore TNF-α secretion in ex-vivo stimulated PBMCs [28]. 
 Another potential target is the PD-1/PD-L pathway: septic patients show an increased 
expression of PD-1 on T cells which lead to inhibition of cell proliferation, induction of IL-10 
secretion, apoptosis and anergy. Different studies have observed that block of this axis is able to 
improve survival in murine models of sepsis. So far antibody anti-PD-1 and anti PD-L have been 
tested, in humans, only to treat different types of cancer inducing a restoration of T cell activity 
[29]. In septic shock the PD-1 expression on T cells and/or PD-L expression on antigen presenting 
cells could be used as biomarkers of T cell exhaustion to drive anti-PD-1 and anti PD-L antibody 
administration. Other inhibitory receptors on T cell surface, such as TIM-3, LAG-3 and CTLA-4, 
BTLA could be used for the same purpose (biomarkers of immune dysfunction and target for 
neutralizing antibodies) in sepsis and septic shock but clinical trials are still lacking [30].  
 The use of recombinant interleukins in order to improve lymphocytes survival and function 
has been only experimented in humans in HIV and cancer patients, but the potential benefits of 
these pleiotropic molecules in septic shock have been demonstrated in animal models. IL-7 has an 
anti-apoptotic effect on T cell and is a crucial factor for lymphocyte production, maturation and 
proliferation [31]. In different murine models of sepsis, the use of IL-7 is able to restore depleted T 
cells in lymphoid organs, induce T cell proliferation and INF-γ secretion leading to a significant 
improvement in survival [32]. IL-15 appears an interesting option too: in addition to anti-apoptotic 
and function-enhancing properties on lymphocytes, displays also effects on innate immune cells: 
promotes survival of dendritic cells and contributes to natural killer-dendritic cell interactions [33].  
 Among the few immunomodulatory treatments experimented on human sepsis and septic 
shock, more data exists on the effect of intravenous immunoglobulins administration. The 
pleiotropic effects of these molecules resulting in a modulation of the immune response and the 
reduction of circulating IgG and IgM in the first days of septic shock are the rationale for their use 
in these pathologies [34, 35]. Two preparations obtained from plasma of healthy donors are 
available: polyclonal standard IgG (IVIG) and IgM-enriched (IgGAM) formulation. Both 
preparations are able to determine pathogen clearance but the higher killing on gram-negative 
bacteria is obtained with IgM-enriched immunoglobulins [36]. Trautmann et al measured a higher 
rate of LPS-specific antibodies in IgGAM because of the concentration of these antibodies in IgM 
fraction which is known to be the most relevant in the neutralization and clearance of toxins [37]. 
Despite the relative high number of studies evaluating this additional therapy, the scarce number 
of patients and heterogeneity in terms of type of preparation, dosages and durations hinder the 
significance of the results observed. Nevertheless, a meta-analysis of 18 studies reveals a 
reduction in mortality using polyclonal Ig compared to control arm, in particular protocols with 
lower doses associated with longer duration of treatment reach more favorable outcome [34]. 
Differently from studies on GM-CSF and INF-γ, where a biomarker of immunosuppression such as 
HLA-DR expression has been used, in the case of polyclonal Ig administration neither patient’s 
plasma concentration of Ig nor other immunological markers has been tested to guide the 
administration. The importance of this issue is underlined by the studies on GM-CSF and the 
observation by Berlot et al that the timing in the administration of IgGAM influences the outcome 
of patients: the delay in the treatment is a significant and independent predictor of the odds of 
dying [38]. Considering the measurement of immunoglobulin plasma levels as markers to identify 
patients which could take advantage in the Ig administration, recent studies have observed that a 
single measurement of circulating Ig at the onset of septic shock is not effective, on the contrary 
their kinetic during the first week seems able to differentiate survivors from non-survivors in 
particular regarding IgM [39]. Because of the outstanding variations in immune response of each 
patient the identification of useful biomarkers appears fundamental to identify those with 
immune dysfunction and to develop a customized immune-therapy. 
 
CONCLUSIONS 
Septic shock in patients suffering from infection supported by MDR or XDR gram negative is 
definitely a challenge for intensivists worldwide. Taking into account that the multi-resistant 
germs are spreading worldwide, the probability to face with a patients with septic shock sustained 
by MDR or XDR bacetria is no longer an extraordinary event. The application of the Surviving 
Sepsis Campaign guidelines [40] and timely administration of antibiotics are often ineffective due 
to the poor immunological status of these patients [41]. Therefore, the use of adjunctive 
supportive therapies for restoring immune function seems to be very attractive and promising. 
Unfortunately, to date there is no scientific sound validation on these alternative strategies and 
appropriate clinical trials are urgently needed. 
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